Option Care Health, Inc. (OPCH) Stock Price & How to Invest

Option Care Health (Nasdaq: OPCH) delivers medications through intravenous and other infusion therapies in patients' homes and at alternate-site suites, covering both acute needs (like post-hospital antibiotics and nutrition) and chronic conditions (such as immune, neurologic, and inflammatory diseases). It runs a nationwide network of pharmacies and nursing infrastructure, partners with drug manufacturers for distribution, and contracts with payers and health systems, making it the largest standalone player in a fragmented home-infusion market where the top few providers hold roughly a third of share.

The picture changed in early October 2026. Private-equity firm Clayton, Dubilier & Rice and drug distributor McKesson agreed to acquire Option Care for $32.05 per share in cash, valuing the company at about $5.8 billion including debt and representing a premium of roughly 37% over the October 5 close. CD&R is expected to own about 51% and McKesson about 49% at closing, with McKesson investing about $1.4 billion and gaining a framework to potentially buy CD&R's interest later. The deal needs Option Care shareholder approval and regulatory clearances, and it is expected to close in the first half of 2027, after which the shares would stop trading on Nasdaq. Option Care withdrew its 2026 guidance and said it will remain a separate company led by its existing management.

Before the offer, the business was a defensive, cash-generative operator working through a soft patch. Trailing revenue is about $5.69 billion, growing only about 2% in the latest quarter as chronic-inflammatory-drug (CID) portfolio headwinds, including Stelara and biosimilar census resets, dragged on the top line. Trailing net income is about $210 million on a thin 3.7% profit margin, because much of the revenue is drug pass-through cost. The shares jumped on the announcement: they were up about 44% over three months as of October 16, 2026, roughly flat for the year (down about 3% year to date), and several brokers, including Jefferies, UBS, Barrington and Morgan Stanley, downgraded the stock to neutral-style ratings since the remaining upside is limited to the deal price.

The central risk is deal risk. The take-private requires Option Care shareholder approval and regulatory approvals, and a combination involving a major drug distributor could draw antitrust scrutiny; a legal review of the proposed takeover has also been reported. If the deal broke, the shares could fall back toward pre-announcement levels, since the 37% premium is what lifted them. The upside is effectively capped near $32.05 while the deal is pending, and the time to an expected first-half 2027 close ties up capital. The underlying business risks still matter if the deal fails: the CID drug-portfolio headwind tied to Stelara and biosimilar transitions, thin gross margins (about 19%) on high drug pass-through revenue, sensitivity to reimbursement and payer contract terms, competition from CVS Coram and Optum-affiliated Naven Health, and about $1.27 billion of debt against roughly $197 million of cash.

8 analysts publish price targets on OPCH, averaging $30.03 against a $31.20 price as of October 2026, or -3.7%. The published targets run from $23.00 to $33.00, a moderate spread, and the ratings split 0 buy, 11 hold, 0 sell. Over the last six months there has been 1 raise and 9 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full OPCH forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Option Care Health, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. The pending CD&R and McKesson take-private. The dominant factor for OPCH now is the $32.05-per-share cash offer. The most optimistic published target, $33.00, assumes this works close to its best case.

The case against. The central risk is deal risk. The most pessimistic target, $23.00, is roughly what OPCH is worth if this bites instead.

Read the full bull and bear case on OPCH, including what would have to change to break either one. Walnut is not an investment adviser.

Yes. Option Care Health, Inc. (OPCH) has had one share split in the last 10 years:

• 1:4 on February 3, 2020, so every share held became 0.25 shares.

A split changes the share count and the price per share and leaves the value of a holding unchanged. Someone holding $1,000 of OPCH the day before the 1:4 split held $1,000 the day after, in more shares at a proportionally lower price. Historical prices from before the date are normally shown split-adjusted, which is why a long-run chart shows no cliff.

Splits matter mainly because they make older price figures confusing to compare by hand, and because a board choosing to split is usually signalling that the price has run up far enough to feel awkward for smaller buyers. Neither is a reason to buy or sell.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Option Care Health, Inc.'s investor relations page or your broker.

• Deal price: $32.05 per share in cash (CD&R and McKesson)
• Deal value: ~$5.8B including debt
• Expected close: First half of 2027
• Revenue (TTM): ~$5.69B (~+2% YoY in Q2 2026)
• Net income (TTM): ~$210M (~3.7% margin)
• Market cap: ~$4.7B
• P/E (trailing / forward): ~24x / ~15x

OPCH's valuation is now set by the $32.05 cash offer rather than by earnings multiples. At a close near $31.27 on October 16, 2026, the stock trades about 2.5% below the deal price, a spread that reflects time to closing and the risk the transaction is blocked or voted down. Option Care withdrew its 2026 guidance on announcing the deal, so the earlier profit targets no longer apply.

If you want OPCH exposure as part of a larger bundle rather than directly, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

Other names that sit close to OPCH: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get OPCH exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (FESM), which spreads the position across many companies. Or build it into a focused thematic portfolio, so OPCH sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where OPCH fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Option Care Health is a scaled, profitable infusion-services operator that has agreed to be taken private at $32.05 per share in cash by CD&R (about 51%) and McKesson (about 49%). Until the deal closes, OPCH behaves less like an operating story and more like a merger-arbitrage position: the upside is capped near the offer price and the main risk is the deal failing.

Whether OPCH is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is OPCH a buy or a sell?, and where the stock could go from here in the OPCH stock forecast.

For income investors, whether OPCH pays a dividend and how the payout looks is covered in does OPCH pay a dividend? And to weigh OPCH against a peer, read the full side-by-side comparisons: OPCH vs CVS and OPCH vs UNH.